Zobrazeno 1 - 10
of 670
pro vyhledávání: '"Bruce D, Cheson"'
Autor:
Sriram Balasubramanian, Brendan Hodkinson, Stephen J. Schuster, Nathan H. Fowler, Judith Trotman, Georg Hess, Bruce D. Cheson, Michael Schaffer, Steven Sun, Sanjay Deshpande, Jessica Vermeulen, Gilles Salles, Ajay K. Gopal
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 61-73 (2022)
Abstract Background The single‐arm DAWN trial (NCT01779791) of ibrutinib monotherapy in patients with relapsed/refractory follicular lymphoma (FL) showed an overall response rate (ORR) of 20.9% and a median response duration of 19.4 months. This bi
Externí odkaz:
https://doaj.org/article/8e668f1ebce046fb90165c45e83463d9
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 4, Pp 1-10 (2021)
Abstract Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexo
Externí odkaz:
https://doaj.org/article/15deeebcca0044969732fd32c9b87a96
Autor:
Anas Younes, John M. Burke, Bruce D. Cheson, Catherine S. Diefenbach, Silvia Ferrari, Uwe H. Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Jeff P. Sharman
Publikováno v:
Blood Advances. 7:1488-1495
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) and is curative in ∼60% of patients. Atezolizumab is a humanized immunoglobul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fc1b97a21d171847f261eab8a339b3c
https://doi.org/10.1182/bloodadvances.2022008344
https://doi.org/10.1182/bloodadvances.2022008344
Autor:
Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps
Publikováno v:
Haematologica, Vol 106, Iss 9 (2021)
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhib
Externí odkaz:
https://doaj.org/article/1f8e5a0d250d49f8bc29eb2cbf686fb6
Autor:
Toby A. Eyre, Nicole Lamanna, Lindsey E. Roeker, Chaitra S. Ujjani, Brian T. Hill, Paul M. Barr, Erick Lansigan, Bruce D. Cheson, Maryam Yazdy, John N. Allan, Joanna Rhodes, Stephen J. Schuster, Chadi Nabhan, Alan Skarbnik, Lori Leslie, Prioty Islam, Katherine Whitaker, Catherine C. Coombs, Hande H. Tuncer, John M. Pagel, Ryan Jacobs, Allison M. Winter, Neil Bailey, Andrea Sitlinger, Anna H. Schuh, George Follows, Christopher P. Fox, Danielle M. Brander, Mazyar Shadman, Anthony R. Mato
Publikováno v:
Haematologica, Vol 106, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/ad08843e37b24e96ad4960bf18e8f92a
Autor:
Paolo Ghia, Steven E. Coutre, Bruce D. Cheson, Jacqueline C. Barrientos, Peter Hillmen, Andrew R. Pettitt, Andrew D. Zelenetz, Sanatan Shreay, Michael Hallek, Richard R. Furman
Publikováno v:
Haematologica, Vol 105, Iss 10 (2020)
Externí odkaz:
https://doaj.org/article/9855e6dd543348bdb5a1554b9616880d
Publikováno v:
Leukemia Research Reports, Vol 14, Iss , Pp 100200- (2020)
Clinically apparent neurological involvement by chronic lymphocytic leukemia (CLL), especially ocular manifestations, is rare. Standard diagnostic approaches for neurological or ocular CLL, including neuroimaging, have low yield and sensitivity and C
Externí odkaz:
https://doaj.org/article/df1b08135f054905ad3712ad4cb6e381
Autor:
Chaitra Ujjani, Hongkun Wang, Alan Skarbnik, Neel Trivedi, Pari Ramzi, Nadia Khan, Bruce D. Cheson
Publikováno v:
Blood Advances, Vol 2, Iss 7, Pp 762-768 (2018)
Abstract: Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL) include the addition of targeted therapies. The combination of lenalidomide and rituximab demonstrated an overall response rate (ORR) of 66% with a com
Externí odkaz:
https://doaj.org/article/45baaa80a4f74cdcb6f0751ed011b580
Autor:
Muhammad Saad Hamid, Sarah C. Rutherford, Hyejeong Jang, Seongho Kim, Krish Patel, Nancy L. Bartlett, Mary-Kate Malecek, Marcus P. Watkins, Kami J. Maddocks, David A. Bond, Tatyana A. Feldman, Gabriela Magarelli, Ranjana H Advani, Michael A Spinner, Andrew M. Evens, Mansi Shah, Sairah Ahmed, Deborah M. Stephens, Pamela Allen, Michael T. Tees, Reem Karmali, Bruce D. Cheson, Maryam Sarraf Yazdy, Christopher Strouse, Neil A. Bailey, John M. Pagel, Radhakrishnan Ramchandren
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e435-e442
The utility of dose escalation after positive positron emission tomography following 2 cycles of ABVD (PET2) for Hodgkin Lymphoma (HL) remains controversial. We describe the United States real-world practice patterns for PET2 positive patients.Data w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d328ef0cdd5cc4127f2987077e3d9c
https://doi.org/10.1016/j.clml.2021.12.012
https://doi.org/10.1016/j.clml.2021.12.012
Autor:
Anthony R. Mato, William G. Wierda, Matthew S. Davids, Bruce D. Cheson, Steven E. Coutre, Michael Choi, Richard R. Furman, Leonard Heffner, Paul M. Barr, Herbert Eradat, Sharanya M. Ford, Lang Zhou, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, John C. Byrd
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
The utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter’s transformation versus chronic lymphocytic leukemia (CLL) progression after ibrutinib and/or idelalisib was assessed in a post hoc analysis of a pha
Externí odkaz:
https://doaj.org/article/2eb9743dadf8446b8ea8d2185f71d8bf